Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HTR1E | P28566 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1397809 | 0.89 | NPC1 (0.61) | NPC1RAB9APGRALDH1A1MEN1 | |
| SCHEMBL1397747 | 0.82 | GRIN2D (0.48) | NPC1PGRALDH1A1MEN1KMT2A | |
| SCHEMBL1397817 | 0.77 | NPC1 (0.61) | NPC1RAB9APGRALDH1A1MEN1 | |
| SCHEMBL5130200 | 0.75 | RAB9A (0.56) | NPC1RAB9APGRALDH1A1MEN1 | |
| SCHEMBL18992826 | 0.75 | NPC1 (1.00) | NPC1RAB9APGRALDH1A1MEN1 | |
| SCHEMBL3540640 | 0.74 | NPC1 (0.69) | NPC1RAB9APGRALDH1A1MEN1 | |
| SCHEMBL3539080 | 0.73 | NPC1 (0.63) | NPC1RAB9APGRALDH1A1MEN1 | |
| SCHEMBL18992722 | 0.72 | NPC1 (0.69) | NPC1RAB9APGRALDH1A1MEN1 | |
| SCHEMBL8087323 | 0.72 | NPC1 (0.64) | NPC1RAB9APGRALDH1A1MEN1 | |
| SCHEMBL5547525 | 0.71 | NPC1 (0.60) | NPC1RAB9APGRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985759-B2 | Dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them | MATRIX LABORATORIES LTD. (IN) | 2011-07-26 | — | — | US | disclosed |
| EP-2004601-B1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS AND PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MATRIX LAB LTD (IN) | 2011-03-02 | — | — | EP | disclosed |
| US-20100160302-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS AND PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MYLAN LABORATORIES LIMITED (IN) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160302-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS AND PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | NPC1 110/4885RAB9A 2811/4885PGR 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.